Phillips-Medisize Corp. has signed an agreement to supply Sanofi with insulin pen components for its diabetes treatment. Phillips-Medisize has expanded its automated production line at its injection pen component plant in Kontiolahti, Finland, to accommodate Sanofi’s demand.   The new pen is an easy-to-use disposable pen for the administration of lixisenatide and the finished device being produced for the Japanese market. The manufacturing involves injection molding technology, assembly and tray...